Eye Surgery in China vs Korea: the comparison turns on your diagnosis

Almost everything written about China versus Korea for eye surgery compares them on price, and almost all of it is unusable: published Korean prices for the same cataract operation differ by a factor of two to three depending on whether you are reading a domestic page or an international-patient package. China is the cheaper of the two on like-for-like terms, and that is not the interesting difference. The interesting difference is structural. Korea has a large, promoted, government-measured inbound patient industry that is 62.9% dermatology and 87.7% clinic-level. China has no such industry at all, and its international eye patients go to academic tertiary hospitals. Which of those shapes suits you depends entirely on what is wrong with your eyes.

Korea publishes its numbers, and they are not eye numbers

This is the part of the comparison nobody writes down, and it is available because Korea's Ministry of Health and Welfare publishes it. In 2025 Korea received 2.01 million foreign patients from 201 countries — the first year above two million since the statistics began in 2009, following 610,000 in 2023 and 1.17 million in 2024, for a cumulative 7.06 million. It is a genuinely impressive machine. Here is what that machine treats:

Ophthalmology does not appear in the ministry's named departments at all. It sits inside the residue. Nearly three quarters of Korea's inbound patients are there for skin and cosmetic surgery, and the ministry attributes the 2025 surge to three things by name: visa-free entry for Chinese group tourists, VAT refunds on cosmetic and plastic-surgery procedures, and the global reach of K-beauty. Those are the drivers of the number. None of them is an eye.

The second table matters more, because it describes where the care physically happens:

Eighty-eight per cent of it is clinic work, and 87.2% of it happens in Seoul. That is a system optimised — very well optimised — for receiving a healthy adult, treating them in a day, and sending them to a hotel. Eye surgery divides almost perfectly along that line.

Which eye problems are clinic-shaped, and which are not

The useful question is not "which country is better" but "does my problem fit a clinic or a hospital". Nothing in this table is unique to Korea or China — it is how ophthalmology is organised almost everywhere — but it predicts which country's inbound system is built for you.

Two of those rows deserve a warning rather than a recommendation. Glaucoma is a chronic disease managed over decades, and pressure control belongs with a doctor you can reach — our glaucoma and retina page argues against travelling for it more often than for it. Diabetic macular oedema treated with injections is a cadence problem, not a trip: eight or nine injections in a first year cannot be delivered by any single visit to any country, and the drug-price section of our diabetic retinopathy page explains why a patient treated with repackaged bevacizumab at around $70 a dose loses money by flying anywhere.

The price comparison is less usable than it looks

You will find pages claiming Korea is 20–30% cheaper than China for a multifocal cataract, and pages claiming Korea costs twice as much. Both cite real numbers. The reason they disagree is that "the price in Korea" is at least three different numbers, and the same is true of China.

China's column is our standard partner-hospital fee schedule, researched July 2026. The middle column is the international-patient package pricing published in that market, researched July 2026 — the same basis we use for every destination in our cataract-abroad comparison. The right column is what Korean clinics advertise on their domestic-facing pages, gathered August 2026 and converted at roughly ₩1,490 to the US dollar, the implied rate in the Korean government's own 2025 spending figures.

Notice that the two Korean columns differ by roughly a factor of two to three for the same operation. That is not an error in either source. It is the same gap our which-country guide documents for India, where international-patient packages sit well above the domestic list price a local resident would recognise, and it is the same distinction we draw about China's own national reimbursement prices, which are settlement prices for scheme enrollees and not what a visitor pays. A domestic Korean figure is also usually a figure for someone whose National Health Insurance is paying part of the bill. You are not that person.

So the defensible statements are narrower than either marketing claim:

• On like-for-like international-patient terms, China is cheaper — roughly $800–1,200 per eye against $2,000–3,000 for a monofocal lens.
• The premium-lens gap is much narrower than the monofocal gap, because a trifocal from Zeiss or Alcon costs a similar amount wholesale everywhere. The cheaper the surgery around it, the more the lens dominates the bill.
• The difference is not large enough to be the deciding factor once a long-haul fare, a week of accommodation for the review schedule and a companion are in the budget — and neither is it a difference in what you are buying.
• Any price claim in either direction is unusable until you hold two written itemised quotes that state the lens model and power, what is included, and whether the figure is per eye or for both.

Where the gap does open: the consumable-versus-theatre-time test

There is a rule that predicts which procedures show a real cross-border saving and which do not, and it works on any destination including ours. Ask what the bill is mostly made of.

• Theatre time, equipment hours and surgical staffing — vitrectomy, orbital decompression, corneal grafting, strabismus surgery, trabeculectomy. These are labour-dominated, and labour is where a genuine structural gap exists. This is where China's advantage over both Korea and Western private care is largest and most durable.
• A globally priced consumable — a premium intraocular lens, a drug vial, a per-case licence fee. These are bought by every country from the same handful of manufacturers, so the gap narrows and can invert. It is exactly why the premium-lens comparison above is a wash, and why a US patient on bevacizumab should not travel for injections at all.

The one large exception runs in China's favour, and it is a drug rather than a procedure. China's National Medical Products Administration licensed a domestic IGF-1R antibody for thyroid eye disease in March 2025; after national price negotiation the standard eight-infusion course is roughly $12,400–13,200 in drug cost, against a published US originator price of about $146,000 per course. That is the widest single gap on this site, and it exists because the consumable itself is domestically made. The catches are set out in full on our thyroid eye disease page: the course runs about twenty-one weeks, so it cannot be a medical trip, and rehabilitative surgery has to wait for the disease to go inactive.

Where Korea is genuinely the better answer

A comparison that concedes nothing is an advertisement. Korea is better than China at several things that matter to a patient, and some of them will decide your case.

• Being received. Korea has a statutory framework for attracting international patients, a government accreditation programme for hospitals that serve them, registered institutions, and clinics whose entire commercial model is the foreign daycase. Turning up is smooth in a way that a Chinese public tertiary hospital, which was not built for you, is not.
• Elective clinic work. Refractive surgery and routine premium-lens cataract are precisely the shape Korea's system serves best, and 87.7% clinic share is the proof.
• Geography, for some readers. Seoul is two to three hours from Tokyo, Taipei or Shanghai and well connected to Southeast Asia, which makes a return visit for review realistic rather than theoretical. If your surgery needs a second look at six weeks, a short-haul destination beats a better hospital twelve hours away.
• Cosmetic oculoplastics. If what you actually want is a cosmetic eyelid result rather than a functional repair, Korea is the world's centre for it. That is not work we arrange, and we would rather say so than sell you something adjacent. Our ptosis page draws the functional-versus-cosmetic line if you are unsure which side of it you are on.

Where China is the stronger route

The case for China is narrower than most facilitator pages claim, and stronger where it holds.

• Subspecialty depth in one institution. China's leading eye hospitals are large academic centres with separate cornea, retina, glaucoma, oculoplastics and paediatric services on one campus. That matters when the diagnosis changes mid-work-up — when the cataract turns out to sit in front of a diabetic macula, or the thin cornea turns out to be keratoconus. Our hospitals guide sets out which centre is strong at what.
• Volume in the procedures that need it. Volume is not a quality guarantee and we do not present it as one, but for standardised operations it correlates with consistency, and China's surgical volumes in cataract and cornea are among the largest anywhere.
• Theatre-time-dominated pricing. Per the test above: the more of your bill is surgical hours, the more China saves you. Our full price guide carries the dated ranges.
• Domestically licensed biologics. The thyroid eye disease case is the clearest, and China's domestic anti-VEGF tier is widening for the same structural reason.

The number that should reset your budget in either country

Korea's government commissioned an economic analysis of its 2025 inbound patients. Foreign patients and their companions spent KRW 12.5 trillion — about US$8.4 billion — of which KRW 3.3 trillion, about US$2.2 billion, went to medical services.

Roughly three quarters of what gets called medical-tourism spending is not treatment. It is flights, hotels, food, transport, companions and shopping. That is the most useful single figure in this comparison and it is not about Korea: it is about how to budget a medical trip anywhere, China included. If you are choosing between two countries on a $400 difference in the surgical fee, you are optimising the small line. Price the fare, the accommodation for the whole review schedule, the companion, and the second trip if there is one.

Our insurance and records page covers what does and does not reimburse any of it — the short version being that planned elective surgery abroad is self-funded almost everywhere, and that the EU cross-border directive European readers often rely on applies only within the EU and EEA, so it covers neither Korea nor China.

One statutory detail worth knowing

Under Korea's Act on Supporting of Overseas Expansion of Medical Services and Attraction of International Patients, foreign-patient bed occupancy is capped at 5% at tertiary hospitals and 8% at general hospitals, to protect domestic access. The ministry reported actual occupancy below 1% at both tiers in 2025, so the cap constrains nobody today.

It is worth knowing anyway, for two reasons. It tells you what Korea's system is designed to protect, and inpatient beds are precisely what complex eye surgery needs. And it is the mirror image of the Chinese position: China has no equivalent statute because it has no equivalent inbound industry — no promotion, no cap, and no referral-commission market for public tertiary hospitals to participate in. We treat that as a warning about convenience and not about competence, and it is the same argument our which-country guide makes about why China is missing from every medical-tourism round-up.

Six questions that separate the two, once you have quotes

1. Which institution tier is this, and does it match my diagnosis? A clinic quote for work that belongs in a tertiary hospital is the single most common mismatch in both countries.
2. Who is the named operating surgeon, and what is their subspecialty? Not the clinic, not the coordinator, not the group.
3. What happens if the diagnosis changes on the day? Ask which department the case would be handed to, and whether it is in the same building.
4. What is the full review schedule, and how much of it must happen in-country? This usually decides China versus Korea more honestly than price does.
5. Is the quote itemised, and what is the lens, drug or platform model? An itemised bill with implant model, power and serial number is what your doctor at home will need.
6. Who signs the flight clearance, and when? It is a clinical judgement made on the day by the operating surgeon. Nobody — no clinic, no concierge, ourselves included — can commit to it in advance. Our flying after eye surgery guide sets out the procedure-by-procedure windows, including the absolute no-fly periods after gas tamponade.

What neither country fixes

Both destinations share the same three unsolved problems, and a page that only compares them against each other hides all three.

• Follow-up happens at home. Your four-week and three-month reviews, your pressure checks, your next injection: those belong to a doctor in your own city. For corneal grafts, glaucoma surgery, cadence-treated retina and paediatric cases we treat a named home specialist arranged before travel as a condition, not a suggestion.
• Complications are geography. Endophthalmitis after any intraocular procedure typically declares itself within one to seven days. Wherever you have surgery, the question is who you can physically reach in that window.
• Nobody reimburses you. Travel medical insurance excludes by design the treatment you flew to receive, and no national system funds planned elective surgery in either country for a non-resident.

And the answer that beats both countries more often than either will admit: if your own health system funds the operation, have it there. A funded cataract in the Netherlands, Belgium, Indonesia or under Hong Kong's subsidy programme costs less than the flight alone. We set that out, country by country, in the non-US coverage comparison.

Frequently asked questions